WuXi Biologics expands

Source: Xinhua | 2018-06-21

WUXI Biologics, a Hong Kong-listed biopharmaceutical company, said yesterday that construction of a US$20 million integrated biologics conjugate R&D and manufacturing center has started in Wuxi in neighboring Jiangsu Province.

To be operational in 2019, the 6,000-square-meter facility will provide integrated solutions from concept to commercialization of biologics conjugates including Antibody-Drug Conjugates (ADCs) and other protein conjugates.

ADCs are complex molecules composed of an antibody linked to a biologically active cytotoxic drug, which has been adopted for a number of innovative treatments for targeted tumor therapy.